Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3815-3822

  Jia, Wang ^a,b   Sander, Andrew J ^b   Jia, Guijun ^a   Ni, Ming ^a   Liu, Xiao ^a   Lu, Runchun ^a   Jiang, Wen G ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Death receptor 3; Invasion; Pituitary adenoma; VEGI

Indexed keywords

CORTICOTROPIN; DEATH RECEPTOR 3; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; PROLACTIN; THYROTROPIN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; CAVERNOUS SINUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOCRINE FUNCTION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE STUDY; SELLA TURCICA; TUMOR BLEEDING; TUMOR INVASION; TUMOR VOLUME;

DEATH RECEPTOR-3; INVASION; PITUITARY ADENOMA; VEGI;

ADENOMA; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885015248     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Blevins LS Jr., Verity DK and Allen G: Aggressive pituitary tumors. Oncology (Williston Park) 12: 1307-1312, 1315; discussion 1315-1308, 1998.
2. Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A and Hedley-Whyte ET: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753-761, 1993.
3. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A and Cantore G: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9: 103-113, 2002.
4. Ozer E, Canda MS, Ulukus C, Guray M and Erbayraktar S: Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89: 54-59, 2003.
5. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA and Gittoes NJ: Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58: 141-150, 2003.
6. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K and Stefaneanu L: Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas. Endocr Pathol 10: 229-235, 1999.
7. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R andYu GL: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
8. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM and Wei P: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
9. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, Grinham CJ, Brown R and Farrow SN: A death-domaincontaining receptor that mediates apoptosis. Nature 384: 372-375, 1996.
10. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD and Ashkenazi A: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol 6: 1669-1676, 1996.
11. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J and Dixit VM: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274: 990-992, 1996.
12. Kaplan MJ, Ray D, Mo RR, Yung RL and Richardson BC: TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164: 2897-2904, 2000.
13. Kaptein A, Jansen M, Dilaver G, Kitson J, Dash L, Wang E, Owen MJ, Bodmer JL, Tschopp J and Farrow SN: Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett 485: 135-141, 2000.
14. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K and Yagita H: Multiple pathways of TWEAK-induced cell death. J Immunol 168: 734-743, 2002.
15. Zhang N, Sanders AJ, Ye L and Jiang WG: Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med 24: 3-8, 2009.
16. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
17. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
18. Gout S, Morin C, Houle F and Huot J: Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 66: 9117-9124, 2006.
19. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D and Ashkenazi A: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703, 1998.
20. Ge Z, Sanders AJ, Ye L, Mansel RE and Jiang WG: Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro. Oncol Rep 29: 1356-1364, 2013.
21. Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee JM: Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388: 913-920, 2005.
22. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL and Li LY: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.
23. Witz IP: The involvement of selectins and their ligands in tumorprogression. Immunol Lett 104: 89-93, 2006.
24. Wu SF, Liu TM, Lin YC, Sytwu HK, Juan HF, Chen ST, Shen KL, Hsi SC and Hsieh SL: Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrowderived dendritic cells in nonobese diabetic mice: From regulatory mechanism to clinical implication. J Leukoc Biol 75: 293-306, 2004.
25. Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL and Li LY: The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 179: 3742-3751, 2007.
26. Buchfelder M: Management of aggressive pituitary adenomas: Current treatment strategies. Pituitary 12: 256-260, 2009.
27. Dinh JQ MA, Palmer MB and Grosshans DR: Particle therapy for central nervous system tumors in pediatric and adult patients. Transl Cancer Res 1: 137-149, 2012.
28. Figarella-Branger D and Trouillas J: The new WHO classification of human pituitary tumors: Comments. Acta Neuropathol 111: 71-72, 2006.
29. Knosp E, Steiner E, Kitz K and Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-617; discussion 617-618, 1993.
30. Vieira JO Jr., Cukiert A and Liberman B: Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Surg Neurol 65: 130-135, 2006.
31. Vieira JO Jr., Cukiert A and Liberman B: Magnetic resonance imaging of cavernous sinus invasion by pituitary adenoma diagnostic criteria and surgical findings. Arq Neuropsiquiatr 62: 437-443, 2004.
32. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr., Lloyd RV, Davis DH, Guthrie BL and Schoene WC: Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 79: 804-812, 1997.
33. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr., Vidal S, Kovacs K, Raz A and Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 63: 2251-2255, 2003.
34. Giorgi RR, Correa-Giannella ML, Casarini AP, Machado MC, Bronstein MD, Cescato VA and Giannella-Neto D: Metallothionein isoform 3 gene is differentially expressed in corticotropinproducing pituitary adenomas. Neuroendocrinology 82: 208-214, 2005.
35. Higai K, Shimamura A and Matsumoto K: Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367: 137-143, 2006.
36. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D and Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9: 899-909, 1995.
37. Subramaniam M, Koedam JA and Wagner DD: Divergent fates of P-and E-selectins after their expression on the plasma membrane. Mol Biol Cell 4: 791-801, 1993.
38. Steegmaier M, Levinovitz A, Isenmann S, Borges E, Lenter M, Kocher HP, Kleuser B and Vestweber D: The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373: 615-620, 1995.